Media Advisory - Malaria Symposium: How science and policy can shield the vulnerable endangered by malaria Français
MONTREAL, June 16, 2016 /CNW Telbec/ - Medicines for Malaria Venture (MMV), in association with McGill University and Structural Genomics Consortium (SGC), is pleased to invite media representatives to a solution-oriented summit on the global issue of malaria and how cutting –edge science and political support can make a difference to the lives of the most vulnerable in countries where this disease is endemic.
What: |
Malaria Symposium |
Who: |
Medicines for Malaria Venture (MMV) |
McGill University |
|
Structural Genomics Consortium (SGC) |
|
When: |
Monday, June 20th 2016 |
Time: |
9:00 am to 5:30 pm |
Where: |
The McGill New Residence, |
3625 Avenue du Parc |
|
Plateau Mont-Royal, Montréal |
The following topics will be covered at the event by a panel of renowned Canadian and international experts in drug discovery and development:
- The Challenge of Malaria today
- Canada's response to the malaria challenge
- Clinical challenges
- Antimalarial drug discovery
- Biological and genetic targets and structures
*Note to media: For the occasion, Dr. David Reddy, CEO of MMV, will give an opening and a closing statement as well as a presentation on malaria eradication, considered one of the major challenges facing the global health community today. He will also be available on site for media interviews from 10:30 to 11:00 am on June 20th.
**Note to media: M. Marc Miller, Member of Parliament for Ville-Marie - Le Sud-Ouest - Île-des-Soeurs, will be present as a keynote speaker from 9:15 to 9:35 am.
RSVP: Please confirm your attendance to Frederic Bourgeois-LeBlanc at [email protected] before 2:00 pm on Friday, June 17
About MMV:
Medicine for Malaria Venture (MMV) is a not-for-profit partnership launched in 1999 committed to accelerating progress against malaria, and ultimately to defeating this terrible disease. With its global network of over 400 public and private partners, including several in Canada, MMV is focused on developing medicines to cure, treat and prevent malaria. To date, they have brought forward six new medicines that are saving hundreds of thousands of lives. Through partnerships, MMV welcomes the continued and new commitment from Canada to help make this goal a reality. With this support the eradication of malaria is set to be one of the biggest public health success stories of modern times.
------
SOURCE Medicines for Malaria Venture (MMV)
RSVP and interview requests: Frederic Bourgeois-LeBlanc, (514) 282-4732, [email protected]
Share this article